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1Summary
BACKGROUND
Opioid dependence is associated with substantial medical, psychological and social problems. 
Long-term opioid replacement therapy is the most common treatment option internationally. Ac-
cording to Norwegian health authority regulations, medication-assisted rehabilitation (MAR) is 
generally only available for persons aged 25 years or more who have treatment experience from 
non-medical programmes. The aim of this research project was to assess the feasibility of short-
term buprenorphine replacement therapy programmes for dependent opioid users who were not 
eligible for the ordinary long-term programmes. I also aimed to explore individual differences in 
the patient group.  
METHODS
The research project comprised three studies. First, a literature review was undertaken to assess 
post-treatment abstinence rates in former patients in methadone or buprenorphine replacement 
programmes. Second, 75 dependent opioid users in outpatient counselling were recruited to a 9-
month buprenorphine replacement programme and followed up for two years. Third, 65 study 
participants’ personality profiles were compared to those of an age-matched norm sample. 
RESULTS
We identified 14 studies in the literature review. The pooled abstinence rate across the studies was 
33%.  For individuals who had left treatment voluntarily or on staff recommendations, the pooled 
abstinence rate was 48%, versus 22% for persons who had been discharged involuntarily or against 
staff recommendations. 
Forty study participants (53%) completed the 9-month buprenorphine replacement programme. 
Three non-completers died during detoxification. At two-year follow-up, the number of deaths had 
increased to five. Nine participants were abstinent from all opioids (illicit and prescribed), and 
thirty-seven participants were still in or had returned to opioid replacement therapy. 
2The opioid-dependent sample was less emotionally stable, less outgoing and less conscientious 
than the non-clinical sample. 
CONCLUSION 
Abstinence-orientated buprenorphine replacement therapy did not seem to be a feasible alterna-
tive to current treatments. 
3Sammendrag (Summary in Norwegian) 
BAKGRUNN
Opioidavhengighet er forbundet med betydelige medisinske, psykologiske og sosiale problemer. 
Internasjonalt er den vanligste intervensjonen langsiktig substitusjonsbehandling med opioider 
som metadon eller buprenorfin. Blant norske helsemyndigheters kriterier for inntak i legemiddel-
assistert rehabilitering (LAR)  er en nedre aldersgrense på 25 år og ikke-medikamentell behand-
lingserfaring. Formålet med dette forskningsprosjektet var å undersøke hvor hensiktsmessig det er 
å tilby tidsavgrenset substitusjonsbehandling med buprenorfin til avhengige opioidbrukere som 
ikke fylte LAR-kriteriene. Det var også et mål å utforske individuelle forskjeller i pasientgruppa.  
METODE
Forskningsprosjektet omfattet tre studier. Først gjorde vi en litteraturgjennomgang for å undersø-
ke i hvilken grad tidligere substitusjonspasienter var avholdende fra opioider etter avvenning fra 
metadon eller buprenorfin. Så rekrutterte vi 75 opioidavhengige polikliniske pasienter til 9 måne-
ders substitusjonsbehandling med buprenorfin og oppfølging i to år. Til sist sammenliknet vi per-
sonlighetsprofilen til 65 studiedeltakere med et aldersmatchet normutvalg.  
RESULTATER 
Vi identifiserte 14 studier i litteraturgjennomgangen. Den gjennomsnittlige andelen personer som 
var avholdne fra opioider etter behandling var 33 %. For personer som hadde forlatt behandlingen 
frivillig og etter behandlers anbefaling var andelen 48 %, mot 22 % for personer som var skrevet ut 
mot sin vilje eller uten anbefaling.  
Førti studiedeltakere (53 %) fullførte nimånedersprogrammet med buprenorfin substitusjonsbe-
handling. Tre av dem som ikke fullførte døde under avvenning fra buprenorfin. Ved toårsoppføl-
gingen var antallet døde steget til fem. Ni deltakere var avholdende fra alle slags opioider (både 
illegale og foreskrevne), og trettisju deltakere var fortsatt i, eller hadde returnert til, substitusjons-
behandling.
4Det opioidavhengige utvalget var mindre følelsesmessig stabile, utadvendte og pliktoppfyllende 
enn det ikke-kliniske utvalget.  
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Research aims 
The general objective of this research project was to assess the feasibility of abstinence-
orientated buprenorphine replacement therapy. We also aimed to explore individual dif-
ferences and the use of various assessment instruments. More specifically, the research 
aims were to: 
1. Estimate to what extent opioid abstinence can be expected from former main-
tenance patients (paper I)
2. Examine possible relationships between patient and treatment characteristics, 
and abstinence rates (paper I)
3. Assess the need for research in the field of abstinence-orientated maintenance 
treatment in general, and time-limited buprenorphine maintenance in par-
ticular (paper I) 
4. Examine changes in drug use and other relevant patient variables across three 
phases of treatment: stabilisation, maintenance and detoxification (paper II) 
5. Assess completion, retention and compliance (paper II) 
6. Identify possible predictors of programme completion (paper II) 
7. Investigate how follow-up outcomes two years after study entry were related 
to participants’ programme completion status (paper III)  
8. Examine the relationships between follow-up performance and current ago-
nist therapy status (paper III) 
9. Examine whether there is a distinct personality pattern associated with opioid 
dependence (paper IV). 
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The opioids comprise opiates (e.g. opium, morphine, codeine) derived from the poppy 
plant, as well as semi-synthetic compounds (e.g. heroin) and synthetic compounds (e.g. 
methadone, buprenorphine).  In addition to their analgesic properties, opioids elicit an 
exaggerated sense of well-being or happiness, and this makes them likely to attract 
abuse.
People who use opioids regularly are at risk of developing a dependence syndrome. 
Opioids stimulate central opioid receptors in the brain, where the ø-receptor probably is 
the most important with regard to dependence (1). For individuals with opioid depend-
ence, the use of opioids, most often heroin, has become a central aspect of their lives. 
They usually spend most of their days acquiring and administering the drug, and show 
little interest in other activities they used to appreciate. With time, people become toler-
ant to opioids so larger doses are needed to achieve the desired effect. Many people who 
are dependent on opioids wish to stop using them, but find it too difficult and tend to 
relapse. As the opioid effect withdraws, individuals typically experience intense physical 
and psychological discomforts. Among these are nausea, tremors, chills or profuse sweat-
ing, muscle and stomach cramps, diarrhoea, loss of appetite, insomnia, anxiety and irri-
tability.
Opioid dependence syndrome is a diagnosis in the WHO diagnostic system ICD-10 (code 
F11.2) (2), requiring three of the following criteria to be met in the last 12 months: 
• Strong desire or sense of compulsion to take opioids 
• Difficulties in controlling opioid-taking behaviour 
• Withdrawal state on cessation or reduction of opioid use 
• Tolerance to opioids (increased dose needed to obtain desired effect) 
• Progressive neglect of alternative pleasures or interests 
• Persistent use despite harmful consequences. 
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It has been estimated that the prevalence of opioid dependence is one percent in adults 
over 15 years globally (3). The condition imposes substantial burdens of ill-health and 
social problems at both individual and societal levels. Due to the respiratory depressant 
effect of opioids, overdoses may be fatal. An estimate from the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) suggests a mortality rate among opioid 
users that is 20 times higher than in corresponding age groups without opioid use (4). 
Findings from the National Treatment Outcome Research Study (NTORS), a large prospec-
tive cohort study conducted in the UK, showed that overdose was the most common 
cause of death among drug users (5). One third of the deaths were caused by other 
events, such as self-inflicted injury, accidents, violence or medical conditions. Other 
prevalent health problems among dependent opioid users include infectious diseases 
due to intravenous use (e.g. hepatitis C, HIV/AIDS) and psychiatric disorders. Opioid de-
pendence is also associated with social problems, such as unemployment, homelessness 
and acquisitive crime.  In sum, the burden of illness and social problems can be heavy.  
As a result, users need complex services.   
The aetiology of opioid dependence is not entirely established. A number of aspects are 
believed to be involved, including biological, psychological and socioeconomic factors 
(6;7). For instance, Robinson and Berridge’s incentive-sensitisation model of substance 
dependence offers an explanation for the persistent craving for substances, even when 
tolerance is developed and the euphoric effect decreased, or after long periods of absti-
nence (8;9). In their view, neurobiological processes that occur in conjunction with sepa-
rate episodes of substance use can lead to increased feelings of needing drugs over time. 
According to the self-medication hypothesis (10-12), emotionally unstable individuals 
may experience that their psychological distress is alleviated when they use opioids. In 
that respect, using opioids can be seen as a response in a negative reinforcement process 
(13;14) – it removes an aversive stimulus (psychological distress), reinforcing the re-
sponse (increased tendency to use opioids). Opioid use has also been associated with 
sensation seeking and engagement in risk behaviours (15-17). Zuckerman views sensa-
tion seeking as a personality trait with biological foundations, making some people more 
inclined to engage in risk behaviours than others (18). Paper IV considers the role of per-
sonality in opioid dependence, comparing personality traits in a group of stabilised de-
pendent opioid users with traits in a non-clinical age-matched sample. 
OPIOID REPLACEMENT THERAPIES 
In the 1960s, US psychiatrists Vincent P. Dole and Marie Nyswander conducted the first 
trials where opioid-dependent patients were treated with the synthetic opioid 
methadone (19). The purpose of this treatment was to replace the use of illicit opioids 
with a long-acting agent that prevented both withdrawal symptoms and craving for 
opioids.  
Methadone was first synthesised in Germany in 1937. During World War II, there was a 
shortage of morphine in Germany, and methadone became an important analgesic for 
surgical use. Like other opioid agonists, methadone binds to and activates the ø opioid 
receptor (20). Methadone has a long half life (15 to 55 hours), allowing single daily doses. 
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Side effects of methadone include respiratory depression, sleep disturbances, weight 
gain, sexual dysfunction and constipation. The research literature regarding methadone-
related cognitive impairment is too inconsistent to draw conclusions (21). Although used 
as an analgesic in some cases of cancer in some countries, its most common clinical use 
today is opioid replacement therapy for opioid dependence.   
Internationally, methadone maintenance treatment (MMT) is the most widely used 
opioid replacement therapy alternative. MMT typically involves daily supervised dosing 
of oral methadone dissolved in syrup, accompanied by some kind of psychosocial inter-
vention. Numerous studies with various designs have consistently shown that metha-
done maintenance therapy is associated with increased retention in treatment, and re-
ductions in illicit opioid use, criminal activities, infectious diseases and mortality (22-26).   
In addition to methadone, the opioid replacement therapy umbrella embraces other 
compounds, such as slow-release morphine, levo-alpha-acetylmethadol (LAAM), heroin 
and buprenorphine. Buprenorphine has become the most common alternative to 
methadone in opioid replacement therapy, except in France, where ten time more pa-
tients are treated with buprenorphine than with methadone (27).  
Furthermore, replacement therapies can be used with different treatment objectives. 
While maintenance treatment has a long-term or indefinite perspective, there are also 
time-limited treatment options, aiming at abstinence from all opioids. Maintenance 
treatment with buprenorphine (BMT) or methadone (MMT) appear to have similar out-
comes, although retention in BMT is lower than in MMT (6;28). When it comes to absti-
nence-orientated opioid replacement therapies, however, many addiction medicine clini-
cians and researchers suggest that buprenorphine is more suitable than methadone. 
THE NORWEGIAN SETTING 
The prevalence of dependent opioid users in Norway is difficult to determine. A 2002 
survey estimated the number of injecting opiate users to between 11,000 and 15,000 (29). 
We assume that the majority of injecting opiate users are dependent and that intrave-
nous injection is the most common route type of administration among people with 
opioid dependence, so we will use the 11,000 – 15,000 estimate in the rest of this thesis. 
A different 2002 survey showed that primary heroin users were the second largest pa-
tient group after primary alcohol users in Norwegian treatment and care facilities for 
substance use disorders (30). The treatment system has traditionally relied heavily on 
three non-medical modalities: inpatient detoxification, outpatient counselling and resi-
dential programmes. In 1998, however, medication-assisted rehabilitation (MAR) based 
on methadone maintenance therapy was introduced. 
Norwegian inpatient detoxification services treated 8,573 persons with substance use 
disorders in 2002 (30). These treatment episodes constituted 48% of all inpatient treat-
ment episodes for the patient group that year. Inpatient detoxification involves the pro-
vision of psychosocial and/or medical care with the aim of alleviating  withdrawal symp-
toms. Detoxification programmes are usually not regarded as treatment per se, but 
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rather as a gateway to long-term, abstinence-orientated treatment (31;32). In Australia, 
the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) com-
pared entry rates into post-detoxification treatment for five different detoxification 
methods (33). Entry rates were: 65% for buprenorphine outpatient detoxification, 63% for 
detoxification under sedation, 42% for detoxification under anaesthesia, 27% for outpa-
tient detoxification with symptomatic medications, and 12% for inpatient detoxification 
with symptomatic medications. So, the detoxification method used in Norway had the 
lowest entry rate. Other studies have reported poor completion rates in inpatient detoxi-
fication (32;34-39).  For detoxification completers, however, abstinence rates at 6-18 
months’ follow-up have been reported in a range from 15% to 79%.  
There were 14,323 individuals with substance use disorders in Norwegian outpatient 
clinics in 2002, attending an average of 8.3 sessions each (30). Outpatient counselling 
typically consists of regular individual and/or group sessions with eclectic therapeutic 
approaches. It is delivered at a relatively small cost and can be adjusted to patients in 
different situations with different needs. Findings from the US Drug Abuse Treatment 
Outcome Study (DATOS) showed that outpatients were younger, more likely to be em-
ployed and to be criminally active, and less likely to be dependent on heroin than pa-
tients in other treatment modalities (40). Furthermore, the research team concluded that 
outpatient counselling was less effective for heroin dependence than for other substance 
use disorders. The DATOS results regarding outpatient treatment for opioid dependence 
have been supported by Norwegian findings (30;41).  
In 2004, approximately every second treatment programme in Norway was a residential 
rehabilitation unit (30). These programmes are for the most part based on theoretical, 
ideological or religious approaches, such as therapeutic communities, the Minnesota 
model and evangelical centres. The main treatment goal is usually abstinence from psy-
choactive substances. Programme duration varies from 3 months to 1-2 years. According 
to Norwegian and UK studies, a majority of residential patients are opioid dependent 
(30;42), while cocaine dependence appears to be the most prevalent substance use disor-
der among US patients (40). Residential programmes are often challenged by high drop 
out rates and relapse to daily substance use (43-49). The National Treatment Outcome 
Study (NTORS) reported a general opioid abstinence rate of just over 50% one year after 
discharge from UK residential treatment programmes (50). 
Medication-assisted rehabilitation (MAR) has become a nationwide treatment option 
since its introduction in Oslo in 1998. Methadone is the preferred replacement agent, but 
buprenorphine was introduced as an alternative in 2001. MAR has a long-term perspec-
tive, where integrated psychosocial services play a central role. In 2003 the number of 
MAR patients across the country approached 3000 (51), or somewhere between 20% and 
27% of the estimated opioid dependent population. The mean age of patients was 38 
years, and 69% were male.
Admission criteria have been characterised as rather restrictive compared to other coun-
tries:
• Age ² 25 years 
• Long-term drug misuse dominated by opiates 
• Reasonable extent of admissions to non-medical, abstinence-orientated treatments 
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Although exceptions from these criteria can be granted in cases of serious disease or 
when indicated by comprehensive considerations, MAR is ruled out as a treatment op-
tion for young opioid-dependent adults and/or those with little treatment experience.  
Norwegian practitioners and health authorities have therefore shown some interest in 
short-term, abstinence-orientated replacement therapy as an alternative for those under 
the MAR age limit. 
ABSTINENCE-ORIENTATED BUPRENORPHINE REPLACEMENT THERAPY 
Buprenorphine was first marketed as an analgesic in the USA in the 1980s. In 2001, high-
dose buprenorphine treatment for opioid dependence was approved in both the USA and 
in Norway.  
Like methadone, buprenorphine is a synthetic opioid with similar opioid effects. The two 
compounds do differ somewhat in their pharmacological profiles, however (52). Most 
importantly, methadone is a full agonist, while buprenorphine is a partial agonist. Its 
ceiling effect is a product of the partial agonism. While agonists have a linear dose-
response curve, that of buprenorphine is sigmoid. This means that at a certain dose level, 
higher buprenorphine doses will extend the duration of its effects rather than intensify 
them. In a clinical perspective, this gives a potential for alternate-day dosing (52). Per-
haps more importantly, the ceiling effect is associated with a reduced overdose risk. 
Another special characteristic of buprenorphine is its high affinity to the ø receptor. If 
the majority of ø receptors are already occupied by an opioid agonist when buprenor-
phine is taken, the agonist effect will be replaced by the antagonist effect of buprenor-
phine, causing withdrawal reactions (53). It is therefore essential that patients are ad-
vised to leave sufficient time between the last use of an opioid agonist and the first ad-
ministration of buprenorphine. Moreover, when the ø receptors are occupied by bupre-
norphine, there will be an agonist blockade, mitigating the effects of other, “competing” 
opioids (54;55).  
Buprenorphine’s poor oral bioavailability is also an important distinction from metha-
done (53). As it is destructed in the gastrointestal tractus, buprenorphine tablets are ad-
ministered sublingually. It will take five to ten minutes to absorb tablets in this manner, 
implying that supervised administration is more time-consuming than for methadone, 
which is quickly swallowed. 
The opioid withdrawal syndrome on cessation of buprenorphine treatment has been de-
scribed as milder than that associated with withdrawal from methadone or other full 
opioid agonists (56-58). While detoxification from methadone is associated with consid-
erable discomfort of long duration and strong cravings for opioids (59-61), peak with-
drawal from buprenorphine is usually experienced within the first two to five days after 
dosing cessation, with mild symptoms persisting for weeks. 
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Theoretically, short-term buprenorphine replacement therapy may be profitable for 
young and treatment-naïve individuals for several reasons: 
• The ethics of keeping people in treatment longer than necessary is always question-
able.
• Time-limited treatment as opposed to indefinite maintenance would increase patient 
turnover and the total number of patients treated per year.  
• A subgroup of treatment-seeking persons might find an indefinite treatment per-
spective unattractive for different reasons. Some might want to get rid of opioid de-
pendence as such, some might dislike enduring monitoring, and some might experi-
ence conflict between self-fulfilment or ambitions and ongoing therapy.   
• It has been demonstrated that selected individuals are able to detoxify from metha-
done and achieve long-term abstinence (23;24).  
• The pharmacological profile of buprenorphine suggests that it is a better choice than 
methadone in time-limited programmes. 
Bickel et al (62) have compared the efficacy of buprenorphine and methadone in a 90-day 
outpatient detoxification programme. Outcomes were heroin use and retention, and re-
sults were equally poor for both agents. In another study, participants received either 
behavioural therapy or standard psychosocial treatment in addition to a 160-day bupre-
norphine programme (63). The programme completion rate was higher in the behav-
ioural therapy group. A 16-week buprenorphine-reduction study resulted in a completion 
rate of 31%. Previous participation in Alcoholics Anonymous (AA) was a predictor of 
completion (64). Fewer psychiatric symptoms at intake were predictive of treatment 
completion in a buprenorphine treatment programme lasting three to four months (65). 
Only one of 29 patients completed a discontinuation trial consisting of 4 to 12 weeks’ 
maintenance followed by a five-week double-blind dose-reduction phase (66). Paper II 
provides completion outcomes from a prospective study of a 9-month buprenorphine 
programme.
None of the study examples mentioned above reported follow-up outcomes after cessa-
tion of buprenorphine replacement therapy. The research literature on abstinence-
orientated buprenorphine treatment at the time this research project was initiated is 
thus not exhaustive. In Paper I, the research literature was systematically searched to 
identify possible studies containing post-treatment outcomes. Furthermore, post-
treatment outcomes of the 9-month buprenorphine programme are reported in Paper III.  
PROJECT HISTORY 
In 1997 Skien-based psychiatrist Torbjørn Tvedten developed an abstinence-orientated 
buprenorphine replacement therapy programme in response to the poor availability of 
effective interventions for young and untreated heroin users. The programme, consisting 
of a combination of time-limited (12 months) buprenorphine replacement and cognitive 
behaviour group therapy at Tvedten’s private practice, was tried out in cooperation with 
the local social services. Thirty-eight patients were included in the programme; 20 pa-
tients (53%) were discharged due to programme rule violations and 18 (47%) completed 
dose reductions as planned. Among the discharged patients, one was enrolled in a thera-
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peutic community at seven-month follow-up, four had buprenorphine prescribed by 
Danish physicians, two were serving prison sentences, eight had relapsed to regular her-
oin use and four were dead. Outcomes were more favourable for the programme com-
pleters; five had relapsed, one was deceased, but the remaining patients were character-
ised as well-functioning (all outcomes refer to personal communication with Torbjørn 
Tvedten).
The programme was not approved by the health authorities because it was not an ap-
proved research project, and buprenorphine was not a registered agent for the manage-
ment of opioid dependence. In 1999, the programme was forced to an abrupt and prema-
ture end, shortening the planned treatment duration for many patients. Tvedten per-
ceived the preliminary outcomes as promising, and took the initiative to design a uni-
versity based study.   
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Methods  
LITERATURE REVIEW (PAPER I) 
We searched the literature in two batch operations. The first batch was studies of time-
limited or abstinence-orientated opioid replacement therapies, and the second batch was 
studies on termination of opioid maintenance treatment with long-term perspectives.  
We searched MEDLINE, Pre-MEDLINE and PsychInfo for studies published between 1966 
and July 2003. For the first batch, every possible combination of buprenorphine or 
methadone, and short-term, intermediate, time-limited or abstinence-orientated were used 
as search terms. In addition buprenorphine reduction and methadone reduction were 
used separately. Search terms in the second batch were buprenorphine maintenance or 
methadone maintenance combined with detoxification, withdrawal and abstinence. The 
database searches were supplemented with hand searches in reference lists of central 
publications, such as overview articles and textbooks. 
Studies on detoxification, defined as programmes of less than 30 days’ duration, were 
excluded. Patients had to be aged at least 18 years and studies were required to report 
post-treatment abstinence rates and length of follow-up interval.  There were no inclu-
sion criteria regarding study design or other methodological issues. Article titles, ab-
stracts and full text papers were screened by the two authors independently.
Key findings were summarised in meta-analyses. For continuous variables, pooled means 
were calculated by multiplying sample means with the respective sample sizes and divid-
ing the sum of these products by the sum of sample sizes. The corresponding calcula-
tions for categorical variables were to divide the sum of each study’s prevalence by the 
sum of sample sizes. 
CLINICAL STUDY (PAPERS II AND III) 
The study was designed as a time series with one pre-treatment assessment and eight 
follow-up assessments.  It was conducted during 2002 – 2005 at the Unit for Addiction 
   
22
Medicine, University of Oslo, and at five outpatient clinics (PUT) in Oslo (Ullevål), Bærum, 
Hamar, the Grenland area and Kristiansand. Each participant entered the study for two 
years.
Participants 
Seventy-five heroin users in, or presenting for, counselling were recruited from the five 
participating clinics, where opioid replacement therapies were not ordinarily offered. The 
number of participants at each clinic varied from 10 to 28 (Fig 1).  
Figure 1. Participant recruitment 
Inclusion criteria were:  
• Opioid dependence according to ICD-10 criteria (2)  
• Age ² 22 years  
• Motivation for abstinence-orientated buprenorphine therapy.
The age limit was set at 22 years due to Norwegian treatment restrictions, excluding pa-
tients younger than 25 years of age from substitution therapy. The 22-year-olds would 
reach the age of 24 at completion of the study, and would be close to the official age 
limit if they wished to transfer to ordinary maintenance treatment programmes. The 
motivation criterion was chosen in an attempt to exclude participants with a long-term 
maintenance goal. Eligibility criteria assessments were undertaken by clinicians based on 
their professional judgement, often after consulting other clinicians or the Unit for Ad-
diction Medicine.  
Exclusion criteria were:  
• Severe psychiatric or somatic diagnosis  
• Forthcoming imprisonment.  
Included:
75 outpatients with opioid dependence, ² 22 years and motivated for abstinence-
orientated buprenorphine replacement therapy 
Oslo: 18 Grenland: 29 Bærum: 12 Kristiansand: 10 Hamar: 13 
Excluded: 7 
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These criteria were set in order to avoid any harmful effects of the treatment, and to en-
sure that patients were able to attend both counselling sessions and assessments. Seven 
patients were excluded; 3 declined participation, 2 had forthcoming prison sentences, 1 




Clinicians were instructed to conduct treatment as usual, which generally implied multi-
disciplinary, eclectic therapeutic approaches and individual sessions of diverse intensity. 
Six professions were represented: 15 psychologists, 3 nurses, 9 social workers, 3 physi-
cians/psychiatrists, 1 social scientist and 1 teacher. Behavioural therapy group sessions 
were also available for some patients. Counselling was delivered independently of the 
buprenorphine therapy, that is, the termination of one should not automatically imply 
the termination of the other.  
Buprenorphine replacement therapy 
The buprenorphine replacement therapy programme had an upper time limit of 9 
months, including induction and detoxification. We used the sublingual tablet formula-
tion of buprenorphine (Subutex®). Daily, supervised dispensing took place in pharmacies 
for most patients.  Local public health services paid daily home visits to patients living in 
remote areas. Whenever it was impossible to dispense supervised doses (such as Sundays 
and holidays), doses were doubled the day ahead. Trials of alternate-day dosing of bupre-
norphine suggest that this is well tolerated by most patients (56;67-69). No doses were 
administered without supervision.
Patients were instructed to abstain from opioids a minimum of 8 hours prior to their 
first dose of buprenorphine. To prevent early dropout due to insufficient dosages, a 
flexible dosing scheme was used: 2 – 4 mg on Day 1, 6 – 8 mg on Day 2, then 8 – 10 mg 
the following 5 days, after which buprenorphine was individually dosed up to a maxi-
mum of 16 mg daily.  
Systematic 2 mg weekly dose reductions were initiated after week 25, which left suffi-
cient time to pause the dose reductions at some stage if necessary, or to make several 
attempts to detoxify from buprenorphine within the nine-month time limit. Requests 
for continued buprenorphine treatment and transfer to ordinary maintenance pro-
grammes were individually appraised. 
Outcomes and assessments 
Substance use and associated problems were assessed with the Norwegian version of the 
European Addiction Severity Index (EuropASI) (70;71). The EuropASI is a structured inter-
view with focus on seven different problem areas related to substance use:
• Medical health
• Employment status and financial support  
• Alcohol use
• Other substance use  
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• Criminal activity
• Family and social relations 
• Mental health.
EuropASI interviewers were certified after attending a three-day training course. The in-
take interview was conducted prior to the first buprenorphine dose, with follow-up ver-
sions administered at 3, 6, 9, 12, 18 and 24 months thereafter. 
Substance use was also assessed by urine screening at intake and at 3, 6, 9, 12, 18 and 24 
months’ follow-up. Unsupervised urine samples were collected by clinicians or inter-
viewers, and participants were reassured that results were confidential and for research 
use only. The urine specimens were analysed for heroin (by detecting the metabolite 6- 
monoacetylmorphine), methadone, buprenorphine, benzodiazepines, amphetamines, 
cocaine, cannabis and ethanol at the Norwegian Institute of Public Health. Screening was 
performed using immunoassay (EMIT), followed by gas-chromatography/mass-
spectrometry (GC/MS) or liquid-chromatography/mass-spectrometry (LC/MS) for confir-
mation of positive results.   
Current symptoms of psychological distress were assessed by the Revised Symptom 
Checklist 90 (SCL-90-R), a 90-item multidimensional self-report questionnaire designed to 
screen for a broad range of psychological problems (72). For each problem item subjects 
are asked to indicate the degree of discomfort they have experienced the last 7 days. 
Scores range from 0 (no discomfort at all) to 4 (very high degree of discomfort). The 
mean cross-item score, Global Symptom Index (GSI), in a Norwegian normal population 
has been estimated to 0.32 (73). The SCL-90-R was completed by the patients at the clinics 
after a short instruction. The assessment schedule was identical to that of EuropASI and 
urine sample collection.  
To examine psychiatric diagnoses, the Munich Composite International Diagnostic Inter-
view (M-CIDI; 74) was administered. The M-CIDI is a comprehensive, standardised inter-
view for assessment of mental disorders, including substance use disorders, according to 
the definitions and criteria of both ICD-10 (2) and DSM-IV (75). Interviews took place a 
minimum of 5 weeks after buprenorphine induction, when we assumed that patients 
were stabilised. We used a computerised version of the M-CIDI, where the patients’ an-
swers were entered directly and diagnoses automatically produced. Interviewers had at-
tended a three-day training course and were certified administrators. 
Special forms were used for the continuous registration of counselling session atten-
dance, dose changes and dosing attendance.
Statistical analyses 
The statistical package SPSS for Windows, version 11.0 (76), was used in all analyses. Due 
to the quality and quantity of the collected data, analyses were based on a before-and-
after study design rather than a times series, where repeated measures analyses would 
have been more appropriate. Descriptive statistics were calculated as means with stan-
dard deviations (SD) or as percentages. Bivariate analyses of continuous variables were 
performed by t-tests or Mann Whitney tests, and comparisons of categorical variables by 
   
25
chi-square or Fisher Exact tests. Odds ratios with 95% confidence intervals were obtained 
from logistic regression models, controlling for possible confounding variables. 
PERSONALITY TRAIT STUDY (PAPER IV) 
The study was designed as a case-control study, with 65 cases from the clinical study. The 
mean age of the opioid-dependent sample was 26.8 years (SD 3.4; range 22-39). Twenty-
two subjects (34%) were women. 
Non-clinical controls (n = 676) aged 22-39 years were selected from a national database at 
the Norwegian University of Technology and Science, containing scores of 1153 indi-
viduals representing a wide range of the general Norwegian population. The mean age of 
the control group was 26.8 (SD 3.7), and females and males represented 45% and 55%, 
respectively.
The Norwegian version of the Revised NEO personality Inventory (NEO-PI-R) (77;78) was 
used for five-factor model (FFM) personality trait assessments (79). The NEO-PI-R is a 240-
item inventory measuring five personality traits, each containing six sub-traits or facets:
• Neuroticism 
– Degree of emotional stability and proneness to experience negative affects
– Facets: Anxiety, Angry Hostility, Depression, Self-Consciousness, Impulsiveness, 
Vulnerability   
• Extraversion
– Degree of preference for company of other people and dominance in social set-
tings 
– Facets: Warmth, Gregariousness, Assertiveness, Activity, Excitement-Seeking, Posi-
tive Emotions
• Openness to experience 
– Degree of conventionality and adherence to traditions 
– Facets: Fantasy, Aesthetics, Feelings, Actions, Ideas, Values
• Agreeableness
– Degree of egocentricity and competitiveness
– Facets: Trust, Straightforwardness, Altruism, Compliance, Modesty, Tender-
Mindedness
• Conscientiousness 
– Degree of purposefulness, strong will and determination 
– Facets: Competence, Order, Dutifulness, Achievement Striving, Self-Discipline, De-
liberation.
The NEO-PI-R items are statements of personality tendencies accompanied by five-point 
rating scales, ranging from “strongly disagree” to “strongly agree”. Analyses of Norwegian 
NEO-PI-R data have indicated satisfactory reliability coefficients and very similar factor 
structure with other countries (80). 
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A minimum of 5 weeks after buprenorphine induction, when we assumed they had 
achieved a stable state, patients were requested to complete the NEO-PI-R at the clinics. 
Instructions were given both verbally and in writing, and clinic staff members were 
available for answering any questions regarding the inventory.  
Analyses were conducted using the statistical package SPSS for Windows, version 11.0 
(76). Each individual’s T-scores (mean=50, SD=10) were calculated on the basis of a na-
tional norm database.  
Cohen’s d effect sizes (81) were calculated for the differences in T-scores between opioid 
dependent subjects and controls. Statistical power calculations showed that a medium 
effect size difference (d ² 0.50) at the 0.01-level with power = 0.91 could be detected with 
65 participants in the opioid-dependent sample and 676 in the control group.  
ETHICS
Approvals were granted from the Regional Committee for Medical Research Ethics, Nor-
wegian Medicines Agency and the Data Inspectorate. All participants were informed both 
orally and in writing about the study, and signed informed consent forms.  
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Results 
LITERATURE REVIEW (PAPER I) 
Aim 1: To estimate to what extent opioid abstinence can be expected from former 
maintenance patients  
Fourteen studies met the inclusion criteria and were included in the review. The studies 
were mostly prospective cohort studies of former methadone maintenance patients, au-
thored by US researchers in the 1970s. A total of 1902 participants were included in the 
studies. These were selected for detoxification and post-treatment studies from a popu-
lation of 9718 methadone maintenance patients. The mean time interval between de-
toxification from methadone and follow-up assessment was 28 months. 
There were substantial variations in how abstinence was defined in the included studies. 
The term abstinence could involve both opioid and non-opioid substances, and time 
frames from one month up to several years. Further, abstinence did not necessarily im-
ply complete abstention from opioids. It could imply not returning to replacement 
therapy, not relapsing to intravenous use, or no intense use. 
Termination of methadone maintenance therapy could be categorised as either “thera-
peutic” or “non-therapeutic”.  Therapeutic detoxification was characterised as special 
programmes for patients who wished to leave treatment, and were considered by clini-
cians to have reached the treatment goals. On the other hand, non-therapeutic detoxifi-
cation was the result of a process where patients left treatment against clinical advice, 
or were involuntarily discharged because of programme rule violations or programme 
closure. Disregarding the circumstances for termination of methadone maintenance 
treatment, follow-up abstinence was achieved by 611 of 1902 participants (33%; range 
22% to 86%). When “therapeutic detoxification” was compared to “non-therapeutic de-
toxification” the pooled abstinence rates were 48% and 22%, respectively.  
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Aim 2:  To examine possible relationships between patient and treatment characteris-
tics, and abstinence rates  
The cross-study mean age was 30 years. Seventy nine percent were men. The partici-
pants had been in methadone maintenance treatment for an average of 22 months, and 
had used illicit opioids regularly for an average of 7 years. 
Mean methadone doses prior to detoxification ranged from 20 mg to 87 mg. The detoxi-
fication process lasted from 7 weeks to 7 months. Three of the studies reported detailed 
protocols for trials of different detoxification regimes.  Patients were advised to take 
post-detoxification counselling in four studies. 
Relationships between patient or treatment characteristics and post-treatment absti-
nence were examined in 11 studies. Only six of these described a statistical method for 
analysing data.  
Patient characteristics examined for possible abstinence relationships were age, dura-
tion of severity of dependence, time in treatment, detoxification difficulties or duration, 
pre-treatment social problems or polydrug use, ethnicity, criminal behaviour/prison 
sentences, employment/educational level, in-treatment substance use, and gender.  
Treatment characteristics were methadone dose, therapeutic detoxification and psycho-
social support during detoxification.  
Overall, the single characteristic most frequently associated with abstinence was volun-
tary participation in detoxification programmes with eligibility criteria (“therapeutic de-
toxification”). 
Aim 3: To assess the need for research in the field of abstinence-orientated mainte-
nance treatment in general, and time-limited buprenorphine maintenance in particu-
lar
Two of the 14 included studies were designed as randomised controlled trials, compar-
ing different regimes for methadone detoxification. The remaining studies were natural-
istic prospective studies without controls or comparisons. 
Only one study reported abstinence rates after time-limited opioid replacement therapy. 
The agent used in that study was methadone. Buprenorphine was only used in one of 
the studies, and then as a transition between methadone and abstinence. At the time 
this review was conducted, no studies could be identified that reported post-treatment 
outcomes of abstinence-orientated buprenorphine replacement therapy. 
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CLINICAL STUDY (PAPERS II AND III) 
Aim 4: To examine changes in drug use and other relevant patient variables across 
three phases of treatment: stabilisation, maintenance and detoxification  
All 75 participants were interviewed with the EuropASI at study entry. The number of 
participants interviewed after 3, 6 and 9 months was 64 (85%), 55 (73%) and 41 (55%), 
respectively.
At study entry, the mean number of days during the last 30 days with substance use was 
24 for illicit opioids, 13 for sedatives, 3 for amphetamines, 10 for cannabis, 14 for poly-
drug use, 1 for heavy drinking, and 19 for intravenous use. At 3 months, when patients 
were stabilised on buprenorphine, there were statistically significant (p<0.05) reductions 
in all substance use categories. Exceptions were amphetamines and heavy drinking, 
where the frequency of use remained low. Significant reductions were also seen in the 
mean number of days spent experiencing drug problems and engaging in illegal activi-
ties.  
Compared to the 3-month assessments, there was a reversed tendency at 6- and 9-month 
follow-up for all the above variables, although the measures were still significantly re-
duced when held against pre-treatment levels.  
With regard to psychological distress, the mean number of days out of the last 30 experi-
encing psychiatric problems was 11 at baseline and remained stable until the detoxifica-
tion phase at 9 months, when it increased to 18 days (p<0.01). Mean Global Symptom 
Index (GSI) scores decreased from 1.3 at intake to 0.9 and 1.0 at 3- and 6-month follow-
up, respectively. At the 9-month assessment, however, the mean GSI score had returned 
to the intake level.
Three participants died during the detoxification phase. Causes of death were her-
oin/benzodiazepine overdose, suicide and road traffic accident. 
Aim 5: To assess completion, retention and compliance  
Forty patients (53%) completed the buprenorphine programme. Among the non-
completers, 22 (29%) had buprenorphine replacement therapy continued and 10 (13%) 
had dropped out. The last three non-completers were the deceased participants.
At 9 months, patients had attended averagely 19 counselling sessions each, which con-
stituted 74% of scheduled sessions. The 9-month retention rate for counselling was 67 
patients (87%). With regard to medical compliance, 91% of scheduled buprenorphine 
doses had been taken. The mean buprenorphine dose at 3 months was 13.6 mg. 
Aim 6: To identify possible predictors of programme completion  
The number of lifetime previous treatment episodes for substance use disorders was the 
only variable that achieved a significant odds ratio (OR 0.82; 95% CI 0.70-0.97) in a logis-
tic regression model adjusting for clinic allocation and buprenorphine dose at 3 months. 
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Completers had fewer previous treatment episodes than non-completers. Other patient 
characteristics (demographic, psychosocial and psychiatric variables) or treatment fac-
tors (compliance) did not influence completion. 
Aim 7: To investigate how follow-up outcomes 2 years after study entry were related 
to participants’ programme completion status  
Sixty eight participants (91%) were interviewed after two years. At this point, five par-
ticipants were dead, and the remaining two could not be contacted.  The follow-up rate 
based on the number of living participants was 97%. Among the 68 interviewed partici-
pants, 38 were completers and 30 were non-completers.  
Nine completers reported abstinence from all opioids. Completers had been employed 
for 9 of the last 30 days at follow-up, while non-completers had been employed for 2 
days (p=0.012). Otherwise, there were no differences between completers and non-
completers in follow-up performance.  
Relative to measures at study entry, both completers and non-completers had reduced 
the number of days during the last 30 days with street opioid use, sedative use, poly-
substance use and intravenous use.  
Aim 8: To examine the relationships between follow-up performance and current 
agonist therapy status  
Among the 38 completers, 17 (45%) had returned to some kind of opioid agonist re-
placement therapy at follow-up. The number of non-completers in agonist therapy was 
20. So, there were 37 participants in agonist therapy and 31 participants in the no ago-
nist therapy group two years after study entry.  
There were statistically significant differences (p<0.05) between the agonist therapy 
group and the no agonist therapy group with regard to performance during the 30 days 
prior to follow-up assessments. Participants currently in agonist therapy had spent less 
time using street opioids (2 vs. 13 days), using two or more substances (3 vs. 10 days), 
injecting drugs (2 vs. 10 days) and engaging in illegal activities (0 vs. 6 days). In addition 
the agonist therapy group had been employed for 8 of the last 30 days, as opposed to 3 
days in the no agonist therapy group. 
PERSONALITY TRAIT STUDY (PAPER IV) 
Aim 9: To examine whether there is a distinct personality pattern associated with 
opioid dependence
The five-factor model personality profile for the opioid-dependent sample differed con-
siderably from that of the non-clinical controls: NEO-PI-R scores were higher on Neuroti-
cism, lower on Extraversion and lower on Conscientiousness (d = 1.7, -1.2 and -1.6, respec-
tively). The two groups were similar with regard to Openness to experience and Agree-
ableness, but did differ on Agreeableness facets Trust, Straightforwardness and Modesty (d 
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= -1.1; -0.5; and 0.6, respectively). Unexpectedly, there were only modest differences be-
tween the samples in Neuroticism facet Impulsiveness and Extraversion facet Excitement 
seeking.
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Discussion 
SUMMARY OF FINDINGS 
As judged by our literature review (paper I), there were few studies in the research litera-
ture on abstinence after termination of opioid replacement therapies.  Study designs and 
heterogeneity made it difficult to determine a reliable abstinence rate, but the pooled 
estimate of post-treatment abstinence was 33%. Only one of the 14 included studies ex-
amined the outcomes of a time-limited, abstinence-orientated programme, while the 
remaining 13 studies assessed outcomes after termination of long-term maintenance 
therapy. Methadone was the replacement agent in all studies except for one, where bu-
prenorphine was used in the last phase of detoxification from methadone.  
In paper II, we found that 53% of the patients completed the 9-month buprenorphine 
replacement therapy. Compliance and retention were good, and there were reductions in 
substance use during buprenorphine replacement therapy. Psychiatric problems esca-
lated in the detoxification phase. 
Two years after entry into the clinical study, nine participants were abstinent from all 
opioids (prescribed and illicit), 37 were in some kind of opioid replacement therapy and 
22 were not (paper III). The number of deaths had reached five, and two participants 
could not be contacted for follow-up assessments. Current agonist replacement therapy 
status had a larger impact on participants’ performance at 2-year follow-up than their 
programme completion status.  
The personality trait study (paper IV) showed that individuals with opioid dependence 
appear to have a distinct personality profile compared with non-clinical controls. 
METHODOLOGICAL LIMITATIONS 
This research project had an observational approach rather than an effect focus. We ob-
tained an overview of the relevant research literature, we observed outcomes during and 
after buprenorphine replacement therapy, and we described the patient group’s distinct 
personality profile. The observational approach widened the probability of detecting 
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relevant outcomes, but also the probability of findings being spurious. More rigorous 
research designs would have lowered the risk of bias. They would also have made it pos-
sible to determine more decisively the direction of causality.  
Literature review (paper I) 
In the literature review several actions could have been made to increase the specificity 
and sensitivity of the search strategy. First, additional databases, such as the Cochrane 
Library, EMBASE, ISI and CINAHL, could have been searched. Second, search terms could 
have been more elaborate to include as many variations as possible. Third, limiting in-
cluded study designs to randomised controlled trials (RCTs) would have allowed a discus-
sion of abstinence as a treatment effect rather than as an associated outcome. Finally, 
critical appraisals of the included studies would have indicated to what degree the re-
view findings were trustworthy.  
A major reason for conducting a less rigorously designed literature review was our inten-
tion to obtain a broad overview of the existing literature on post-replacement therapy 
outcomes. Previous scoping searches in the research databases had resulted in very few 
identified studies, and none whatsoever on buprenorphine. We wanted to perform a 
more systematic search to verify our preliminary findings.  
Clinical study (papers II and III) 
The most important weakness of the clinical trial was the lack of a control or a compari-
son group. The randomised controlled trial (RCT) is widely recognised as the most reli-
able research design for evaluating the effectiveness of interventions (82;83). Non-
randomised controlled trials and observational studies are not only more prone to bias, 
they tend to overestimate treatment effects (25;84). Nevertheless, there are objections to 
the suitability of RCTs in substance dependence treatment research. Gossop proposes 
some technical and theoretical problems regarding the RCT design for evaluations of in-
terventions for substance use disorders (85): 
• The problem complexity and heterogeneity of people with substance use disorders 
may influence outcome despite random allocation to intervention and control 
groups 
• Patients within one group may respond differently to treatment 
• Selection criteria may exclude a number of representative persons, imposing exter-
nal validity problems 
• There may be important differences between people who accept participation in 
RCTs and those who do not 
• Ethical problems arise concerning control groups being offered no or inferior treat-
ment
• Treatment contents and durations are usually fixed in RCTs, while they are not in the 
real world 
• RCTs do not provide information about what works within a complex intervention 
package
In my view, most of these problems are not exclusive to RCTs in the field of substance 
dependence, and the arguments for conducting RCTs still stand.  
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With a randomised controlled design we would have been equipped to detect proper ef-
fects of time-limited buprenorphine replacement therapy compared with placebo out-
comes. However, the available research evidence at the time suggested that buprenor-
phine replacement therapy was more effective than placebo with regard to in-treatment 
use of illicit opioids and retention (86-89). It therefore seemed unethical to run a study 
where half the participants were offered inferior treatment (counselling only). Further-
more, dependent opioid users can easily determine whether they are given the active 
agent or not, eliminating the advantages of blinding (90). Another alternative was to de-
sign an RCT comparing time-limited buprenorphine replacement therapy with indefinite 
treatment. However, our patient group consisted of individuals who were ineligible for 
or not motivated for indefinite treatment within the current prescription regulations, 
making this route impossible. Finally, we considered inviting additional outpatient clin-
ics to participate with patients as non-randomised controls, but abandoned the idea be-
cause of the ethical issues. We also felt we were unlikely to obtain many representative 
controls, because they would have to take part in a full assessment scheme lasting two 
years but without the benefits of extra treatment. 
To include a sufficient number of participants, we chose to carry out a multi-centre 
study. Clinicians were given the responsibility for appraising study eligibility, adminis-
tering questionnaires, collecting urine samples and submitting them for analysis, as well 
as managing both counselling and buprenorphine therapy. Most of these tasks were new 
to a majority of clinicians, and were added to an already substantial workload. We 
learned that there were many disadvantages associated with involving clinicians in data 
collection.  
First, we cannot be certain of how each clinician understood and applied the inclusion 
criteria. While it was possible to exclude patients who had been unduly included, there is 
a risk that eligible individuals were not included. To obtain better insight into partici-
pant recruitment, we could have registered sex, age and diagnosis for all the participat-
ing clinics’ patients.  
Second, despite monthly reminders and two-month data collection margins, it proved 
difficult to obtain follow-up data as planned. SCL-90-R questionnaires and urine samples 
were missing for more than 50% of the patients at nine months. At this stage we trans-
ferred the data collection responsibility to the study interviewers, which did improve the 
situation somewhat, but the missing data rate remained high for the urine samples. Fur-
thermore, many of the samples that were collected could not be used to validate self-
reports because the two measures were taken with too great time intervals. As a conse-
quence, no objective verification of abstinence versus non-abstinence was available. Re-
search on the validity of self-reports is inconsistent, with one review concluding that 
“self-reports of drug users are sufficiently reliable and valid to provide descriptions of 
drug use” (91), and another that “the magnitude of drug use underreporting documented 
in this review could seriously bias prevalence estimates and treatment outcome studies” 
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(92). It seems reasonable to assume that underreporting of substance use will not occur 
deliberately as long as participants are assured that answers are confidential.  
Third, the routine for collecting and submitting buprenorphine dosing data failed for 
some patients. For instance, we lack information on doses prescribed and number of 
doses taken during months 7 to 9 for 11 patients (15%). It also became evident that clini-
cians were not always adhering  to the protocol regarding buprenorphine management, 
prescribing too high a dose in one case, and allowing take home doses in a few cases.  
All these problems constitute a substantial threat to the study’s internal validity. They 
could probably have been limited in a more ideal setting, such as a research clinic, per-
mitting closer cooperation between researchers and practitioners and more standardised 
procedures.
The problem of missing data led to a change in analysis strategy. With a time series de-
sign and complete data sets, as planned, we would have been able to carry out analyses 
of variance for repeated measures. However, with unequal numbers of patients and dif-
ferent individuals assessed at each follow up, the time series approach was replaced by a 
before-and-after design. This is particularly evident in Paper II, where each follow-up out-
come is compared to study entry measures. 
Personality trait study (paper IV) 
The case-control design does not determine the direction of causality. On one hand, the 
clinical sample’s distinct personality profile could be understood as part of the aetiology 
of opioid dependence. Several investigations have documented that personality traits are 
remarkably stable (93), that they have a significant hereditary component (94), and that 
they have behavioural implications, i.e., they influence behavior in any situation and 
they contribute to decisions on which situations individuals are motivated to enter and 
participate in (95). On the other hand, the opioid-dependent sample’s personality profile 
could be explained by a shared, distinctive lifestyle associated with long-term substance 
use. There is evidence suggesting that personality traits are less stable, and thus more 
susceptible to external influences, in younger adults than older adults (96).  
The NEO-PI-R was not administered until the sixth week of buprenorphine replacement 
therapy, when patients were assumed to have achieved stability with regard to substance 
use. We do not know, however, to what extent participants were under the influence of 
drugs when completing the personality inventory. The first in-treatment assessments of 
drug use were 3 months after the first buprenorphine dose. At that time, as shown in 
paper II, substance use was modest and significantly reduced since inclusion assess-
ments.
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STRENGTHS OF THE RESEARCH PROJECT 
Major strengths of this research project were the broad and systematic review of relevant 
literature, a 97% follow-up rate at 2 years in the clinical study and statistically solid ob-
servations in the personality trait study. 
With the wide inclusion criteria chosen in the literature review (paper I), we obtained a 
good overview of the various research designs that had been used in this field, as well as 
patient characteristics. And, perhaps most importantly, we ascertained that with our 
search strategy, no previous studies examining outcomes after abstinence-orientated 
buprenorphine replacement therapy could be identified.  We can therefore be quite con-
fident that our clinical study is the very first of its kind.  
In the clinical study, a 2-year follow-up with 73 of 75 patients (97%) accounted for, gave 
us valuable insight in changes that had occurred in association with treatment (paper 
III). At this time, the study sample could be divided in two, either by completion status 
or by current agonist therapy status, allowing group comparisons. Although group allo-
cation was in no way randomised, it made sense to study outcome differences between 
the groups. The findings made it quite clear that whether people completed the time-
limited treatment programme or not was not a key issue. Of far greater importance for 
positive changes in substance use and employment status was the being in agonist re-
placement therapy at follow-up.
The high follow-up rate also allowed assessments of two crucial long-term outcomes for 
the sample as a whole: abstinence and mortality rate. Even though it is not possible to 
show that abstinence or death were treatment effects, we cannot exclude the possibility 
that they were.  If they are effects, one might conclude that one person will die for every 
second treatment success in abstinence-orientated buprenorphine replacement therapy.
Despite a modest number of cases in the personality trait study, differences of medium 
and large effect sizes were found. In addition, a statistical power of 0.91 strongly suggests 
that the personality traits of people with opioid dependence are in fact different from 
those of non-clinical peers. 
RESULTS IN THE LIGHT OF PREVIOUS RESEARCH 
The pooled abstinence rate in our literature review (paper I) was lower than that in 
Milby’s review from 1988  (33% vs. 41%) (97). Possible explanations for an inferior pooled 
abstinence rate in our review are different definitions of abstinence, different number of 
studies included and different time frames for study selection. Our definition of absti-
nence (abstaining from both prescribed and illicit opioids) was probably more conserva-
tive than Milby’s (“staying off methadone”), limiting the number of individuals fitting 
into the category. Also, our pooled abstinence rate was calculated on the basis of twice as 
many single studies, and for a much larger time frame than in the Milby review (1965-
2003 vs 1970-1975).  
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However, regarding the pooled abstinence rate for “therapeutic detoxification”, the two 
reviews were in agreement. An improved prognosis after therapeutic detoxification was 
also found in Magura’s review of negative consequences of leaving methadone replace-
ment therapy (98). 
Our clinical trial appeared to be the first to report post-treatment outcomes of bupre-
norphine replacement therapy (papers II and III). But, there are a few examples in the 
literature of studies reporting in-treatment outcomes and completion rates of time-
limited buprenorphine programmes, as we do in paper II. The post-treatment outcomes 
can be seen in the light of previous research on termination of methadone replacement 
therapy.
Compared to other studies, our clinical study had some favourable outcomes, but also a 
rather discouraging one. First, our participants attended 74% of their scheduled counsel-
ling sessions throughout the first 39 study weeks, which almost doubles the 90-day at-
tendance rate in a study (n=396) where a special psychosocial intervention was given to 
improve compliance (99). Second, the buprenorphine dosing attendance rate in our 
study (91%) confirmed that buprenorphine is well liked by patients, as seen in other 
studies (55;100). Third, our 53%-programme completion rate exceeded what has been 
seen in previous research (3%-44%) (62;64-66;101). Fourth, in-treatment illicit opioid use 
rates have been reported in a meta-analysis of methadone studies to range from 47% to 
76% (102). This contrasts with our observation at 3 months, at which point the mean 
number of days with illicit opioid use during the last 30 days was 2. Finally, our study’s 
in-treatment mortality rate seemed unprecedented. In the Australian research pro-
gramme National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD), for 
instance, there were no deaths during 312 person-years of treatment (103), while the 
mortality rate in our study was 3 out of 75 over a 9-month in-treatment observation pe-
riod.
In a review published in 2001, Magura and Rosenblum posed the question “What are the 
observed consequences of leaving methadone maintenance?” (98). Their main findings 
were that people who left methadone maintenance treatment tended to relapse to illicit 
opioid use and that their risk of dying increased considerably. The 2-year follow-up out-
comes in our clinical study (paper III) support Magura and Rosenblum’s findings. Two 
more participants had died after discontinuation of buprenorphine replacement therapy, 
in addition to the three participants who died during detoxification. Also, the number of 
days during the last 30 days with illicit opioid use had increased from 2.3 at 6-month 
assessment, to 13 days at 2-year follow-up. It seems that our assumption that buprenor-
phine would be more appropriate than methadone in an abstinence-orientated perspec-
tive was flawed. Furthermore, our assumption that young adults with opioid dependence 
would profit from short-term replacement therapy was also flawed. 
Our findings in the personality trait study (paper IV) that persons with opioid depend-
ence scored high on Neuroticism and low on Conscientiousness were in accordance with 
previous US results (104-106), indicating that traits and disorder are related across cul-
tures. Furthermore, the high Neuroticism scores are supportive of the self-medication 
hypothesis: people may use opioids to reduce psychological distress. However, as we do 
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not know the direction of causality, or whether there is a causal relationship at all, Neu-
roticism may, in fact, be a result rather than a cause of long-term opioid use.  
An important difference between Norwegian and US observations, however, was that the 
Norwegian opioid-dependent sample had low Extraversion scores compared to the con-
trols, while there was no distinction between groups on this trait in the US studies. Our 
cases were rather few, and it is not unlikely that low Extraversion was specific for this 
particular group of people and not for Norwegians with opioid dependence in general. 
The difference between American and Norwegian samples could also be an expression of 
cultural differences. 
IMPLICATIONS FOR FURTHER RESEARCH 
There seems to be sufficient research on in-treatment outcomes of opioid replacement 
therapies to suggest that they do reduce illicit opioid use and retain patients in treat-
ment over time (6). Also, although existing studies are few, outdated and methodologi-
cally weak, they do indicate that there may be serious risks associated with terminating 
treatment prematurely (97;98; paper I). An open question still is, “How long is long 
enough?” Some people may need to be maintained on methadone or buprenorphine in-
definitely, while some people will be able to detoxify after a limited time in treatment. 
Ethically and methodologically sound studies should be designed to investigate when to 
terminate treatment for whom. 
The five-factor model of personality has obtained a central position in contemporary 
personality trait theory. The impact of group personality profiles have been examined in 
several fields, including occupational psychology and mental health. Merely describing 
the personality characteristics of individuals with opioid dependence is not enough. We 
need to know more about how personality traits influence prognosis. It could also be 
useful to model treatment programmes using knowledge of the group’s typical personal-
ity profile, and evaluating the effectiveness of such programmes compared to standard 
treatment.
IMPLICATIONS FOR PRACTICE AND POLICY MAKING 
The overall objective of this research project was to evaluate the feasibility of abstinence-
orientated buprenorphine replacement therapy. Based on the findings from the litera-
ture review (paper I) and the clinical study (papers II and III) there is every reason to 
warn policymakers and practitioners that discharging patients from treatment prema-
turely involves a certain risk of serious deterioration, such as relapse and death. 
Opioid replacement therapies are still a controversial issue in Norway. National guide-
lines are being developed as I write, and one of the questions that has been addressed in 
the media with regard to these guidelines is the suggestion of moving the age limit from 
25 to 18 years. Many of the participants in our clinical study were under the age of 25 
and seemed to profit from replacement therapy while in treatment. More importantly, 
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the existing international research evidence on the effectiveness of opioid replacement 
therapy is based on studies where the inclusion criterion regarding age is usually 18 
years. I cannot see any evidence-based reason for the health authorities to keep with-
holding an effective treatment option from adults over the age of 17. 
With regard to personality assessments, they may, along with other standardised as-
sessments, prove useful to the clinician in tailoring an individual course of treatment. 
Knowing that a patient or a patient group is emotionally unstable, introvert and un-
structured could guide the choice of therapeutic method and therapists’ outcome expec-
tations. 
CONCLUSION 
Abstinence-orientated buprenorphine therapy did not prove to be a feasible treatment 
for opioid dependence because of low completion and post-treatment abstinence rates, 
but also because of a considerable number of deaths. 
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